Daily Briefing · 2026-09-30

Still, debate continues over whether this reflects genuine disinflation. Meanwhile, surging bond yields are grabbing attention on Wall Street, with the 30-year Treasury nearing its highest level since 2002. That's raising the risk of a stock market correction as fixed income becomes more competitive with equities. On the regulatory front, the SEC has proposed a rule allowing performance fees on retail private market funds, a move meant to widen access to alternative investments, though it could raise costs for everyday investors. In healthcare, Eli Lilly's experimental amylin drug, when added to Zepbound, helped patients lose up to twenty-three percent of their body weight, though with more side effects, a finding that could reshape the obesity drug race. Separately, Rafael Holdings announced its Phase Three study of Trappsol Cyclo met its primary goals for treating Niemann-Pick Disease Type C, moving it closer to potential approval. In tech, ON Semiconductor is proving it's no longer just a cyclical chipmaker, having diversified into higher-margin automotive and industrial chips. OpenAI unveiled new Private Intelligence offerings at DevDay, aiming to bring secure, on-premise AI deployment to enterprises. Intel's turnaround story is shifting from survival mode toward factory economics, a sign of improving stability. Ericsson's push to recover margins is drawing skepticism, with analysts saying it needs stronger revenue growth to be sustainable. In media, Netflix shares remain fifty percent below their all-time highs, and analysts caution a recovery isn't guaranteed just yet. And in aerospace, SpaceX's successful Starship orbital milestone is being called a major long-term catalyst for space commercialization and satellite deployment. Finally, Datadog is positioning its AI-driven monitoring platform as essential infrastructure for the AI era, backed by strong recurring revenue potential.